NASDAQ: CTNMContineum Therapeutics Inc Stock
$14.25-0.17 (-1.18%)
Updated Dec 11, 2024
CTNM Price
$14.25
Fair Value Price
N/A
Market Cap
$367.33M
52 Week Low
$12.33
52 Week High
$22.00
P/E
N/A
P/B
1.75x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.03
Operating Cash Flow
N/A
Beta
1.86
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CTNM Overview
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CTNM's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Value
C
Growth
C
Momentum
C
Sentiment
C
Safety
C
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CTNM
Ranked#267 of 554
Ranked#267 of 554
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $19.53 | A | |
| $6.45 | A | |
| $120.72 | A |
Be the first to know about important CTNM news, forecast changes, insider trades & much more!
CTNM News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CTNM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CTNM is good value based on its book value relative to its share price (1.75x), compared to the US Biotechnology industry average (5.62x)
P/B vs Industry Valuation
CTNM's short-term assets ($215.14M) exceed its short-term liabilities ($5.81M)
Short-term Liabilities Financials
CTNM's short-term assets ($215.14M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more CTNM due diligence checks available for Premium users.
Valuation
CTNM fair value
Fair Value of CTNM stock based on Discounted Cash Flow (DCF)
Price
$14.25
Fair Value
$42.42
Undervalued by
66.41%
CTNM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.75x
Industry
5.62x
CTNM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CTNM's financial health
Profit margin
Revenue
$0.0
Net Income
-$10.3M
Profit Margin
0%
Assets to liabilities
Assets
$216.0M
Liabilities
$5.8M
Debt to equity
0.03
CTNM's short-term assets ($215.14M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CTNM's short-term assets ($215.14M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CTNM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.2M
Investing
-$30.2M
Financing
$13.0k
CTNM vs Biotech Stocks
Contineum Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.